Skip to main content

The ADEM trial

ADEM trial results published: Methotrexate disappoints in hand osteoarthritis

Monday 11 November: 11:00–12:30, Hall B1, Georgia World Congress Center, Atlanta, USA

Presenter: Christian Roux, Université Cote d'Azur, Nice, France

In this phase III trial, patients with symptomatic erosive hand osteoarthritis were given once weekly methotrexate 10 mg or placebo for 1 year. The primary endpoint is pain at 3 months, and secondary endpoints include clinical and radiographic features.

Back to the ACR/ARP 2019 conference hub